The role of NAFLD in cardiometabolic disease: An update

Miriam Vos; Sarah Faasse; Hayley Braun

doi:10.12688/f1000research.12028.1

The role of NAFLD in cardiometabolic disease: An update

Miriam Vos, Sarah Faasse, Hayley Braun

Division of Gastroenterology, Hepatology & Nutrition

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.

Original language	English
Article number	170
Journal	F1000Research
Volume	7
DOIs	https://doi.org/10.12688/f1000research.12028.1
State	Published - 2018

Keywords

Cardiometabolic disease
Non-alcoholic fatty liver disease
Type 2 diabetes mellitus

Access to Document

10.12688/f1000research.12028.1

Cite this

@article{704759c6da2e46d99876d2ffc6178a1b,

title = "The role of NAFLD in cardiometabolic disease: An update",

abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.",

keywords = "Cardiometabolic disease, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus",

author = "Miriam Vos and Sarah Faasse and Hayley Braun",

note = "Publisher Copyright: {\textcopyright} 2018 Faasse S et al.",

year = "2018",

doi = "10.12688/f1000research.12028.1",

language = "English",

volume = "7",

journal = "F1000Research",

issn = "2046-1402",

}

TY - JOUR

T1 - The role of NAFLD in cardiometabolic disease

T2 - An update

AU - Vos, Miriam

AU - Faasse, Sarah

AU - Braun, Hayley

PY - 2018

Y1 - 2018

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.

KW - Cardiometabolic disease

KW - Non-alcoholic fatty liver disease

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85042156052&partnerID=8YFLogxK

U2 - 10.12688/f1000research.12028.1

DO - 10.12688/f1000research.12028.1

M3 - Review article

AN - SCOPUS:85042156052

SN - 2046-1402

VL - 7

JO - F1000Research

JF - F1000Research

M1 - 170

ER -

The role of NAFLD in cardiometabolic disease: An update

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this